Pikralida sp. z o. o. and Nencki Institute of Experimental Biology conduct the project co-financed from the European Funds named Utilisation of a matrix metalloprotease inhibitor to develop an innovative therapeutic method that prevents the development of post-traumatic and post-stroke epilepsy.
Project no. POIR.01.01.01-00-0235/20 is implemented under the Smart Growth Operational Program 2014 – 2020, Priority Axis I “Support for R&D activites of enterprises”, subaction 1.1.1. Industrial research and developmental activities conducted by enterprises.
The aim of the project is to develop a breakthrough therapeutic solution protecting against the development of post-traumatic and post-stroke epilepsy based on the inhibition of the epileptogenesis process through the activity modulation of the enzymatic protein, matrix metalloprotease 9 (MMP-9). The project covers, among others, the development of the manufacturing technology for the active substance and investigational medicinal product, therapeutic potential analysis for the MMP-9 inhibitor in animal models, and conduction of the pre-clinical and phase I clinical studies.
- Project budget: 21,564,812.50 PLN
- Co-financing of the project from the European Funds: 16,919,633.00 PLN
- Project timeline: 01.01.2021 – 31.12.2023
The project is co-financed by the European Union under the Smart Growth Operational Program. The program is implemented as part of 3/1.1.1/2020 Fast track for Mazovia competition organized by the National Center for Research and Development.
Development of an innovative pilot line and its validation under real conditions using synthesis process of a model active pharmaceutical ingredient.
Development of the innovative formulation of the combination drug dedicated for the geriatric patients in pain pharmacotherapy
Development of an innovative combined preparation dedicated for the treatment of hypertension.
Establishment of a R&D Laboratory of Super Generic Drugs.